Th De 124	ockets Management Br ne Food and Drug Adm epartment of Health & 420 Parklawn Dr.	ninis	tration		D	ate:	
	ockville, MD 20857	ition	to Have Fternity east do n	artun	i doclared "Mishranded"	,	
	Re: 99P-1340/CP 1 — Petition to Have Eternity eau de parfum declared "Misbranded" Dear Sir or Madam:						
						1	la harra Calria Vlainta
Ete tha 210	In May 1999, the Environmental Health Network (EHN) submitted the above petition to have Calvin Klein's Eternity eau de parfum declared "misbranded." I am writing because I fully support this petition and reques that the FDA give it careful attention with regard to your regulations 21CFR Sec. 740.1, 21CFR Sec. 740.2, and 21CFR Sec. 740.10. Regulation 21CFR Sec. 740.10 states:						
	 Each ingredient used in a cosmetic product and each finished cosmetic product shall be adequately substantiated for safety prior to marketing. Any such ingredient or product whose safety is not adequately substantiated prior to marketing is misbranded unless it contains the following conspicuous statement of the principal display panel: "Warning — The safety of this product has not been determined." 						
As	As the petition shows, <i>Eternity</i> contains toxic ingredients and ingredients whose safety have not been substantiated. There is no warning label on its packaging.						
we are	We all have a right to know the status of safety testing of the ingredients in products such as <i>Eternity</i> so that we can protect ourselves and our families from toxic chemicals that may cause health problems. Most people are not aware that most fragrance materials have only limited safety testing. They wrongfully assume these products are safe to use in any setting and are surprised when people complain.						
Like tobacco smoke, the harmful chemicals currently used in these products may affect the health of many people, including: people with asthma, chemical sensitivities, chronic fatigue, and other environmental illness es. Children are particularly vulnerable to toxic chemicals found in products purchased and used by their parents, caregivers and teachers. When I am exposed to fragrance products I can experience any of the following symptoms based upon the chemical fragrance product I encounter:							
	asthma		double vision	0	incoherence	O	nausea
	anaphylaxis -		ear pain		incontinence		nose bleeds
	anxiety, restlessness		eczema		irritability		rashes
Q_	breathing difficulty		eyes, watery or dry		joint aches		seizures
	bronchitis		fatigue		laryngitis		short-term mem. loss
	can't concentrate		flushing		lethargy		sinusitis
	coughing		headaches		lymph nodes swell	D	O
	depression		heart beat irregularity		mood swings		sores, skin/mouth
	disorientation		hives		muscle pain/weakness		swallowing difficulty
	dizziness		hypertension		nasal congestion		tinnitus
Pl frag peoj	rance exposure at wor	k, at anc	illions of people who hav school and in social setti I chemical sensitivities. T	ngs. ˈ	These toxic chemicals ac	t as	powerful barriers to
Sinc	rerely,						
your			1				C 238
99 j	ess; city/st/zip O- / 3	ho fe	els people have a right to know, p	olease			

Janis Greenberg 242 5th Ave. San Francisco, CA 94118-2362



Attn: 99P-1340/CP 1

Dockets Management Branch
The Food and Drug Administration
Department of Health & Human Services, Rm. 1-23
12420 Parklawn Dr.
Rockville, MD 20857

haldlankalalalahallald

· d,